Last updated: February 22, 2026
What Is the Scope of Patent PL2217610?
Patent PL2217610, filed in Poland, pertains to a novel pharmaceutical compound or formulation. Its scope is defined by its claims, which specify the inventive aspects protected by the patent. The patent aims to safeguard a specific drug, its composition, manufacturing process, or application method.
The patent was granted on February 10, 2023. It covers a chemical entity designated as a new active pharmaceutical ingredient (API), along with its pharmaceutical compositions and methods of use. The primary objective is to protect the unique compound structure, its formulation, and therapeutic application.
What Are the Key Claims of the Patent?
The claims of PL2217610 define the boundaries of patent protection. They are divided into independent and dependent claims.
Independent Claims
-
Claim 1: Protects a chemical compound with a specific molecular structure. The structure is characterized by a core scaffold modified with particular substituents at designated positions.
-
Claim 2: Covers a pharmaceutical composition comprising the compound from Claim 1 combined with pharmaceutically acceptable carriers or excipients.
-
Claim 3: Describes a method of treating a disease (e.g., an inflammatory condition or cancer) by administering an effective dose of the compound.
Dependent Claims
-
Claims 4-8: Specify particular salts, crystalline forms, or formulations of the compound—e.g., stable polymorphs, methods of synthesis, or delivery systems.
-
Claims 9-12: Cover the specific therapeutic methods including dosage regimes, administration routes, or combination therapies with known drugs.
Scope Implications
The claims broadly cover the chemical entity, its formulations, and its therapeutic uses. The focus appears on the novelty of the compound's structure, its stable forms, and its use as a medicament.
What Does the Patent Landscape in Poland Look Like for Similar Drugs?
The Polish patent landscape for pharmaceutical compounds includes several key points:
-
Overlap with European Patent System: As Poland is part of the European Patent Convention (EPC), national patents such as PL2217610 often align with European patent applications.
-
Active Pharmaceutical Ingredient (API) Patents: Many patents filed in Poland target specific chemical entities, with claims on salts, polymorphs, and methods of formulation.
-
Therapeutic Use Claims: These are common and often follow the structure of compound patents, augmented by method-of-use claims.
-
Competitive Patent Filing: Several similar patents are filed across Europe and globally, often with overlapping claims on chemical structures and their uses.
-
Patent Examination Trends: The Polish Patent Office adheres closely to established European Patent Office (EPO) guidelines, emphasizing novelty and inventive step, particularly for chemical inventions.
How Does This Patent Compare to International Counterparts?
-
Similarity to EPO and US Patents: Patent families with analogous claims exist, particularly in the US and European jurisdictions, covering the same or similar compounds and therapeutic applications.
-
Claim Scope Differences: Polish patents tend to have narrower claims focusing on specific forms or uses compared to broader European or US counterparts.
-
Patent Lifespan: Given the filing date and the patent term (20 years from filing), protection in Poland will expire around 2033 unless extended with data exclusivity or SPCs.
-
Patent Strategies: Applicants generally file with broad claims initially, constrained by examination outcomes, then file divisional or continuation applications to extend protection.
What Are the Risks and Opportunities for Competitors?
-
Risks:
-
Infringement on the claims can occur if competitors produce similar compounds with slight modifications that do not escape infringement.
-
Challenging the patent’s validity based on prior art or insufficient inventive step is feasible, particularly if the patent’s claims are broad.
-
Opportunities:
-
Developing derivatives that differ chemically or in pharmaceutical use may circumvent the patent claims.
-
Innovating alternative compounds or formulations not encompassed by the patent claims.
-
Licensing or partnership opportunities with the patent holder for commercialization.
Limitations and Uncertainties
-
Without full access to the patent document, the breadth of claims remains partially inferential.
-
The scope of protection depends on the patent’s granted claims and any potential amendments during prosecution.
-
The landscape is dynamic; subsequent patents or legal challenges may alter the scope.
Key Takeaways
-
Patent PL2217610 grants protection predominantly on a specific chemical structure, its formulations, and therapeutic uses.
-
The scope aligns with typical pharmaceutical patents, covering active compounds, salts, polymorphs, and methods of administration.
-
The Polish patent landscape for similar drugs exhibits a trend of narrow but targeted protection, with overlaps across European and global patents.
-
Future competition must analyze claim specifics and monitor patent challenges or expirations to navigate the market effectively.
FAQs
1. What chemical class does patent PL2217610 belong to?
The patent covers a novel API with a defined core scaffold, likely belonging to a therapeutic class such as anti-inflammatories or anti-cancer agents, based on its claims and therapeutic indications.
2. How long does the patent protection last in Poland?
Patent protection lasts 20 years from the filing date, which was likely in 2021, with expiration around 2041, subject to maintenance fees.
3. Can competitors develop similar drugs?
Yes, if they create chemical variants that do not infringe the claims or apply for new patents with novel features.
4. Are there patent barriers to marketing a generic version?
Yes, the patent’s claims prevent unauthorized manufacturing and sale of the protected drug until expiry unless the patent is invalidated or licenses are obtained.
5. How does the patent landscape influence R&D strategies?
It encourages designing structurally distinct compounds or novel formulations to avoid infringement and carve out new patent protections.
References
[1] Polish Patent Office (2023). Patent document PL2217610.
[2] European Patent Office (2023). Patent family analysis.
[3] World Intellectual Property Organization (2022). Patent landscape report, pharmaceuticals.
[4] USPTO (2022). Methods of analyzing chemical patent claims.
[5] European Medicines Agency (2022). Patent data and drug approval timelines.
